Investor Presentation Q1 2018 Audited Results slide image

Investor Presentation Q1 2018 Audited Results

II Introduction to the Company ...with a proven track record of success... Launch: 2001-2005 Established in 2001 under the name "Ibnsina Laborex" in partnership with Pinault Printemps Redoute ("PPR") through its subsidiary Eurapharma Operational Sites 7 12k Clients 2005 7.0% EGP 665mn Revenue IBNLaborex SINA HARMA إبن سينا لابوركس فارما In partnership with PPR KERING IBN Pharma ابن سينا فارما SINA RIGHT ON TIME Expansion: 2009-2012 Investment to add 15 distribution centers & 5 offices, and enhance efficiency through standardizing operational processes Operational Sites 27 30k Clients EGP 2.5bn Revenue 2012 10.5% 2015 S European Bank for Reconstruction and Development ibnsinapharma Growth: 2013-Present Capture market share through implementing value-base differentiation strategy & launch of new revenue streams focusing on enhancing margins Operational Sites cfao EURAPHARMA Turnaround: 2006-2008 Management buy-out of PPR shares, name changed to “Ibnsina Pharma“; optimized cost structure & turned the Company profitable Operational Sites 56 c.41k Clients 2017 Revenue EGP 9.6bn Market Share 7 16k Clients EGP 1.0bn Revenue ibnsinapharma Source: IMS Health; Company Management 2008 8.8% 1Q18 19.5% IN 6
View entire presentation